Document is current
Any future updates will be listed below
-
Authors
Torbicki, Adam https://orcid.org/0000-0003-3475-8832
Channick, Richard
Galiè, Nazzareno
Kiely, David G.
Moceri, Pamela
Peacock, Andrew
Swift, Andrew J.
Tawakol, Ahmed
Vonk Noordegraaf, Anton
Flores, Dayana
Martin, Nicolas
Rosenkranz, Stephan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02310672 at ClinicalTrials.govDocuments that mention this clinical trial
S93 REPAIR: long-term effects of macitentan on the right ventricle (RV) in pulmonary arterial hypertension (PAH)
https://doi.org/10.1136/thorax-2020-btsabstracts.98
Effect of Macitentan in Pulmonary Arterial Hypertension and the Relationship Between Echocardiography and cMRI Variables: REPAIR Echocardiography Sub-study Results
https://doi.org/10.1007/s40119-023-00345-2
P116 Effects of macitentan on right ventricular remodeling in pulmonary arterial hypertension – results from the REPAIR study interim analysis
https://doi.org/10.1136/thorax-2019-btsabstracts2019.259
-
Funding
Funding for this research was provided by:
Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson
- License Information
-
More Information
Article History
Received: 26 October 2023
Accepted: 4 December 2023
First Online: 28 January 2024
Declarations
:
: Adam Torbicki receives consultancy fees from Janssen Pharmaceutical Companies of Johnson & Johnson, Arena Pharmaceuticals Ltd, Bayer, MSD, Pfizer, United Therapeutics, and Janssen, in addition to grant/research support from Janssen Pharmaceutical Companies of Johnson & Johnson and Speaker’s bureau fees from Janssen Pharmaceutical Companies of Johnson & Johnson, AOP, Bayer, MSD and Pfizer; advisory board member for Janssen Pharmaceutical Companies of Johnson & Johnson. Richard Channick serves as a steering committee member, served on an advisory board, and received research grants/support, and speaker fees from Janssen Pharmaceutical Companies of Johnson & Johnson; has served on an advisory board for Bayer; has received consultancy and speaker fees from Bayer and Arena Pharmaceuticals; and has received research grants from United Therapeutics. Nazzareno Galiè is a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received grant support, personal fees, and non-financial support from Janssen Pharmaceutical Companies of Johnson & Johnson, and has received grant support and personal fees from Bayer Healthcare, Pfizer and GSK. David G Kiely is a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson, receives grant/research support from Janssen Pharmaceutical Companies of Johnson & Johnson, Bayer, and GSK, in addition to other financial or material support, including consultancy and speaker fees, from Janssen Pharmaceutical Companies of Johnson & Johnson, Bayer, GSK, Ferrer and MSD. Pamela Moceri has received consultancy fees from Janssen Pharmaceutical Companies of Johnson & Johnson and MSD. Andrew Peacock receives grant/research support from Janssen Pharmaceutical Companies of Johnson & Johnson, Bayer, and GSK, in addition to other financial or material support from Arena Pharmaceuticals Ltd and MSD. Andrew J Swift has received consultancy fees from Janssen Pharmaceutical Companies of Johnson & Johnson and General Electric Ltd, as well as grant support from GSK. Ahmed Tawakol receives consultancy fees from Janssen Pharmaceutical Companies of Johnson & Johnson and Esperion, as well as grant/research support from Genentech. Anton Vonk Noordegraaf receives ongoing grant/research support from Janssen Pharmaceutical Companies of Johnson & Johnson, GSK and MSD and Speaker’s bureau payments from Janssen Pharmaceutical Companies of Johnson & Johnson. Dayana Flores and Nicolas Martin are employees of Janssen Pharmaceutical Companies of Johnson & Johnson. Stephan Rosenkranz has served as a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received research grants from AstraZeneca, Bayer, Janssen Pharmaceutical Companies of Johnson & Johnson and Novartis; has received speaker and/or consulting fees from and/or been an advisory board member for Abbott, Acceleron, Actelion, Aerovate, Altavant, AOP, Bayer, BMS, Boehringer-Ingelheim, Edwards, Ferrer, Gossamer, Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, Novartis, Pfizer, UT and Vifor.
: The study was conducted in compliance with the Declaration of Helsinki and ethical approval was obtained from the independent ethics committee/institutional review board of all participating centers. All patients provided written informed consent, and all echo and cMRI results were centrally assessed by a blinded imaging committee.
